Partner With Us NRI

Lupin Ltd share Price

Company details

6M Return 76.66%
1Y Return 59.47%
Mkt Cap.(Cr) 52,402.46
Volume 669,860
Div Yield 0.35%
OI Chg %
Volume 669,860

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Beat on revenues but margins still below par…
About The Stock

    Lupin is a multinational pharma company engaged in manufacturing & marketing branded & generic formulations, APIs, biotech products as well as OTC medicines across multiple dosage forms & therapeutic categories.

    • It is the third largest generic player (by prescriptions) in the US with 166 generic products (market leader: 44 products; Top 3: 113 products) along with being sixth largest company in Indian pharmaceutical market
    • The company was recently going through a rough patch especially on the US generics front due to plant compliance issues besides margins pressure

    Lupin’s revenues from US remained subdued while profitability was hampered due to high other expenses and impairment charges (₹ 127 crore)

    • Sales were up 2.6% YoY to ₹ 3883 crore
      • EBITDA was at ₹ 226.5 crore, down 68% YoY with margins at 5.8% mainly due to multiple factors namely - 1) higher input cost, 2) double digit price erosion in US, 3) losartan recalls, 4) Solosec litigation payment, 4) lower operating leverage and 5) higher freight cost
    • Adjusted loss of ₹ 525 crore vs. profit of ₹ 460 crore in Q4FY21

Click here for full recommendation

Research view on more stocks

Pharmaceuticals company Lupin announced Q1FY24 results:

  • Sales of Rs 47,421 million in Q1FY24 compared to Rs 36,040 million in Q1FY23, up 31.6% YoY
  • EBITDA of Rs 8,791 million in Q1FY24 compared to Rs 2,379 million in Q1FY23, up 269.6% YoY
  • EBITDA margin of 18.5% in Q1FY24 compared to 6.6% in Q1FY23, up 1,190 bps YoY
  • PBT of Rs 5,588 million in Q1FY24 compared to Rs 23 million in Q1FY23, up 24,516.3% YoY
  • Gross Profit was Rs 31,013 million compared to Rs 25,803 million in Q4FY23, with gross margin of 65.4%
  • Personnel cost was 17.8% of sales at Rs 8,444 million compared to Rs 7,730 million in Q4FY23
  • Manufacturing and other expenses were 31.0% of sales at Rs 14,724 million compared to Rs 13,030 million in Q4FY23
  • Investment in R&D for Q1FY24 was Rs 3,679 million (7.8% of sales)

Commenting on the results, Nilesh Gupta, Managing Director, Lupin said, “Building on the momentum of the last few quarters, we had a strong quarter with good growth across all key markets as we continue to improve our operating margins driven by higher sales, better mix and cost optimization initiatives. Our India branded business has bounced back to double-digit growth despite NLEM price reductions. With the clearance of Pithampur Unit-2 we expect to add to the product approvals for the US region. Getting approvals for important complex generics like Tiotropium DPI, and getting back into the launch tempo with first to market products like Darunavir and additional new product launches will help sustain the growth momentum both in topline and bottom line as we move ahead”.



Result PDF

View Other Company Results


Investment recommendation
Beat on revenues but margins still below par…
Call Date
11 May 2023
Entry Price 760.00
Target Price 740.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Lupin Ltd Stocks COMPARISION


Equity Capital: 12,464.50 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 15,612.36 -19,132.24
LAST 3M 53,075.98 -4,241.70
LAST 6M 58,662.39 138,824.89
LAST 12M 133,944.68 162,473.45
Lupin`s Nagpur Unit I clears USFDA inspection

Sep 29, 2023 l BSE Announcement

Lupin Limited - Press Release

Sep 29, 2023 l NSE Announcement

Lupin Limited - Press Release

Sep 28, 2023 l NSE Announcement

Date Action Type Ratio
Jul 14, 2023 Dividend 200
Jul 14, 2022 Dividend 200
Jul 27, 2021 Dividend 325

Lupin Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Lupin Ltd is in the Pharmaceuticals sector with the Market Capitalization of worth Rs. 44,266.89 crores, it is incorporated in the year 1968. It has a reported consolidated sales of Rs. 4,237.39 crores in June’2021. The company is also listed in the Bombay Stock Exchange (BSE) with the code 500257 and also listed in the National Stock Exchange (NSE) with the code LUPIN.

    Lupin Ltd is an Indian international pharmaceuticals company and is one of the largest generic pharmaceuticals companies globally based on revenue. The company primarily focuses on six areas, namely, paediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti- tuberculosis. Lupin has a global presence with operations spreading across 11 nations and 6 continents. Lupin has a team of over 1400 scientists working at Research 7 development headquarters located near Pune. Lupin ltd meets its corporate social responsibility through The Lupin Human Welfare & Research Foundation set up in 1988. The foundation mainly focuses on rural development projects that have reached over 3400 villages across eight states in the country to date. The promoters of the company own 46.84% of the stake in the company, Foreign Institutional Investors (FII) own 18.6%, Domestic Institutional Investors (DII) own 22.09% of the stake, and others (such as retail investors) hold the balance of 12.47%.

    In June 2021, quarterly net revenue was Rs. 3,314.12 crores, which has increased by approximately 22.97 % from Rs. 2,695.08 crores for the April-June 2020 quarter. The quarterly net profit in June 2021 was Rs. 645.87 crores, which has seen an increase by nearly 77.64 % from a net profit of Rs. 363.58 crores in June 2020. In June 2021, the reported operating profit was at Rs. 2,617.15 crores, which is also increased by 26.76% as compared to an operating profit of Rs. 2,064.73 crores for the quarter ending in June 2020. From Rs. 8.03 in June 2020, the EPS of Lupin Ltd has almost doubled and reached Rs. 14.13 per share in June 2021. LUPIN’s stock closed at Rs. 974.10 on 17th August’2021 (NSE) and has returned -8.29% in the last six months and -2.83% in the previous year.

Registered Address

Kalpataru Inspire 3rd Floor, Off Western Exp HW Santacruz-E, Mumbai, Maharashtra, 400055

Tel : 91-22-6640 2323
Email : info:lupin.com
Website : http://www.lupin.com

Link Intime India Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 500257
Book Closure Date (Month) :
BSE Group : A
ISIN : INE326A01037

FAQ’s on Lupin Ltd Shares

You can buy Lupin Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Lupin Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Oct 04, 2023 03:56 PM the closing price of Lupin Ltd was ₹ 1,151.50.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Oct 04, 2023 03:56 PM, the market cap of Lupin Ltd stood at ₹ 52,402.46.

The latest PE ratio of Lupin Ltd as of Oct 04, 2023 03:56 PM is 53.96

The latest PB ratio of Lupin Ltd as of Oct 04, 2023 03:56 PM is 0.24

The 52-week high of Lupin Ltd is ₹ 1,184.70 while the 52-week low is ₹ 628.00

According to analyst recommendations, Lupin Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app